Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| DCOY | DEFA14A | neutral | 3/10 | Decoy Therapeutics Inc. filed a DEFA14A (definitive additional proxy soliciting materials) providing notice of its 2026 | Jun 4, 2026 |
| LNZAW | 8-K | neutral | 4/10 | LanzaTech's joint venture, Beijing Shougang LanzaTech Technology Co., Ltd., completed its IPO on the Hong Kong Stock Exc | Jun 4, 2026 |
| EBS | PRESS-RELEASE | neutral | 2/10 | Emergent BioSolutions issued a press release announcing its partnership with Victoria's Voice Foundation for National Na | Jun 4, 2026 |
| LNZA | PRESS-RELEASE | bullish | 6/10 | LanzaTech's joint venture, Beijing Shougang LanzaTech Technology Co., Ltd., completed its IPO on the Hong Kong Stock Exc | Jun 4, 2026 |
| CGTX | 8-K | neutral | 4/10 | Cognition Therapeutics filed an 8-K furnishing an investor presentation for the Jefferies Global Healthcare Conference. | Jun 4, 2026 |
| MIRA | 8-K | neutral | 3/10 | MIRA Pharmaceuticals entered into an Amended and Restated Exclusive License Agreement with MIRALOGX LLC, securing worldw | Jun 4, 2026 |
| KAPA | 8-K | neutral | 4/10 | Kairos Pharma issued a mid-year shareholder letter announcing a term sheet to acquire worldwide rights to CL-741, a Phas | Jun 4, 2026 |
| IMNN | 8-K | bearish | 6/10 | Imunon entered into a $10M financing with Streeterville Capital, consisting of $2.5M from 250 shares of non-convertible | Jun 4, 2026 |
| SPRC | 6-K | neutral | 4/10 | SciSparc's majority-owned subsidiary NeuroThera Labs completed the acquisition of a ~54% interest in CliniQuantum Ltd., | Jun 4, 2026 |
| SPRC | PRESS-RELEASE | neutral | 4/10 | SciSparc's majority-owned subsidiary NeuroThera closed its acquisition of a ~54% interest in CliniQuantum for ~CAD$9.5M | Jun 4, 2026 |
| BYSI | 8-K | neutral | 4/10 | BeyondSpring announced a leadership transition effective July 1, 2026: founder/CEO Dr. Lan Huang steps down as CEO (rema | Jun 4, 2026 |
| ABEO | 8-K | neutral | 4/10 | Abeona Therapeutics reported a constructive pre-IND meeting with the FDA regarding ABO-701, a novel T-cell therapy for p | Jun 4, 2026 |
| RZLT | PRESS-RELEASE | neutral | 3/10 | Rezolute announced four presentations at the ENDO 2026 conference, including an oral presentation of previously reported | Jun 4, 2026 |
| SNDX | 8-K | neutral | 5/10 | Syndax Pharmaceuticals entered into subscription agreements to issue $250.0 million aggregate principal amount of 2.25% | Jun 4, 2026 |
| OCUL | PRESS-RELEASE | bullish | 7/10 | Ocular Therapeutix announced its participation at Clinical Trials at the Summit 2026, where it will present multiple dat | Jun 4, 2026 |
| AXSM | PRESS-RELEASE | neutral | 3/10 | Axsome Therapeutics announced presentations of new SYMBRAVO® data at the AHS 68th Annual Scientific Meeting, including p | Jun 4, 2026 |
| AMGN | COURT-RULING | bullish | 5/10 | The Delaware District Court issued a Markman order in a patent case against Amgen, ruling that the claim term 'a functio | Jun 4, 2026 |
| PULM | S-3 | bearish | 5/10 | Pulmatrix filed an S-3 registration statement to register the resale of up to 490,910 shares of common stock by selling | Jun 4, 2026 |
| PHAR | 6-K | bullish | 7/10 | Pharming announced FDA acceptance of its resubmitted sNDA for Joenja (leniolisib) to treat children aged 4-11 with APDS, | Jun 4, 2026 |
| SER | EFFECT | bearish | 7/10 | The SEC declared effective Serina Therapeutics' S-3 shelf registration (File No. 333-296166) on June 3, 2026. This shelf | Jun 4, 2026 |
| GOVX | EFFECT | bearish | 5/10 | The SEC declared effective the S-1 registration statement filed on May 26, 2026, covering up to 7.64 million shares of c | Jun 4, 2026 |
| ALVO | PRESS-RELEASE | bullish | 7/10 | Alvotech resubmitted BLAs to the FDA for AVT05 (Simponi biosimilar) and AVT06 (Eylea biosimilar) after responding to a P | Jun 4, 2026 |
| BIIB | PRESS-RELEASE | neutral | 5/10 | Biogen and UCB presented Phase 3 PHOENYCS GO data at EULAR 2026 for dapirolizumab pegol (DZP) in systemic lupus erythema | Jun 4, 2026 |
| JBIO | PRESS-RELEASE | bearish | 6/10 | Jade Biosciences priced a public offering of 10 million shares at $15.00 per share, expecting gross proceeds of $150 mil | Jun 3, 2026 |
| SYRE | CLUSTER | neutral | 2/10 | CEO Turtle Cameron and CFO Scott Burrows sold a combined $372K in SYRE stock on June 1, 2026, at ~$69.40-$69.75. The CFO | Jun 3, 2026 |
| HALO | CLUSTER | neutral | 2/10 | CEO Helen Torley and a director sold a combined ~$214K in open-market shares on June 1, 2026, at ~$66/share. The CEO als | Jun 3, 2026 |
| EVMN | CLUSTER | bearish | 5/10 | Three top executives at Evommune (CEO, CFO, CLO) sold a combined $1.12M in open-market sales over a 5-day window, repres | Jun 3, 2026 |
| CORT | CLUSTER | neutral | 3/10 | Four CORT insiders, including the CEO, CFO, and two senior executives, sold a total of $5.50M in open-market shares with | Jun 3, 2026 |
| CORT | CLUSTER | bearish | 5/10 | Four Corcept Therapeutics insiders, including the CEO, CFO, and two other senior executives, sold a total of $5.50M in o | Jun 3, 2026 |
| CORT | CLUSTER | neutral | 4/10 | Three top executives at Corcept Therapeutics (CEO, CFO, and a senior officer) sold a total of $7.59M in open-market shar | Jun 3, 2026 |